Eli Lilly & Co (LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Ticker
LLY
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$1.29T
52-week range
$850.51 - $1475.25

Valuation

Share price
$1434.38 (close of Nov 16, 2026)
P/E (TTM)
46.78x
Price to book
31.97x
Price to free cash flow
65.48x
Enterprise value
$1.33T
Book value per share
$45.15

Price performance

PeriodChange
1 day-0.63%
5 days+1.59%
1 month+14.11%
3 months+21.54%
6 months+42.74%
Year to date+33.47%
1 year+39.90%
3 years+143.63%
5 years+456.56%
10 years+1,764.28%
All time+35,344.14%

Short interest

As of
Oct 30, 2026
Short % of float
0.81%
Shares short
7.21M
Days to cover
2.66
Change since prior report
+3.64%
Source
FINRA consolidated short interest

Members of Congress who disclosed LLY trades

Josh Gottheimer · David Taylor · Gilbert Ray Cisneros · Jonathan Jackson · Julie Johnson · Lisa McClain · John Boozman · Marjorie Taylor Greene · Michael Rulli · Val Hoyle · Angus King · Bruce Westerman

And 10 others

Super investors holding LLY

Ken Griffin (Citadel) · Polen Capital Mgmt (Polen Capital Management LLC) · Mairs & Power (Mairs & Power Inc) · Ray Dalio (Bridgewater Associates) · Dodge & Cox (Dodge & Cox Funds) · George Soros (Soros Fund Mgmt) · Stanley Druckenmiller (Duquesne Family Office) · Bill Nygren (Harris Associates LP) · David Katz (Matrix Asset Advisors Inc)

Profitability and growth

Return on equity
77.78%
Return on invested capital
31.19%*
Return on assets
18.35%
Return on capital employed
34.47%*
Gross margin
83.04%
Net margin
31.67%
EBITDA margin
43.91%
Revenue growth
44.70%
Net income growth
94.90%
Free cash flow growth
138.62%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
1.53%
Current ratio
1.39x
Net debt to EBITDA
0.91x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$65.18B
Cost of revenue
$11.05B
Gross profit
$54.13B
EBITDA
$28.62B
Net income
$20.64B
Earnings per share
$23.00
Research and development
$13.34B
Interest expense
$895.00M
Shares outstanding
897.30M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$65.18B$54.13B$20.64B$23.00
2024-12-31$45.04B$36.63B$10.59B$11.76
2023-12-31$34.12B$27.04B$5.24B$5.82
2022-12-31$28.54B$21.91B$6.24B$6.93
2021-12-31$28.32B$21.01B$5.58B$6.15
2020-12-31$24.54B$19.06B$6.19B$6.82
2019-12-31$22.32B$17.60B$8.32B$8.93
2018-12-31$21.49B$16.81B$3.23B$3.14
2017-12-31$19.97B$15.53B-$204.10M-$0.19
2016-12-31$18.31B$14.15B$2.74B$2.59

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3183.04%31.67%77.78%31.19%*
2024-12-3181.31%23.51%74.20%23.73%*
2023-12-3179.25%15.36%48.23%15.87%*
2022-12-3176.77%21.88%57.95%24.34%*
2021-12-3174.18%19.71%60.97%22.16%*
2020-12-3177.66%25.24%106.33%28.39%*
2019-12-3178.85%37.27%-27.23%*
2018-12-3178.22%15.04%29.63%15.56%*
2017-12-3177.73%-1.02%-1.75%5.00%*
2016-12-3177.28%14.95%19.44%11.93%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$7.27B$40.87B
2024-12-31$3.42B$28.53B
2023-12-31$2.93B$18.32B
2022-12-31$2.21B$14.74B
2021-12-31$3.91B$15.35B
2020-12-31$3.68B$16.59B
2019-12-31$2.44B$13.82B
2018-12-31$7.41B$9.20B
2017-12-31$8.03B$9.94B
2016-12-31$6.04B$8.37B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$8.97B$626.00M
2024-12-31$3.76B$646.00M
2023-12-31$792.00M$629.00M
2022-12-31$5.73B$371.10M
2021-12-31$6.06B$342.80M
2020-12-31$5.11B$308.10M
2019-12-31$3.80B$312.40M
2018-12-31$4.31B$279.50M
2017-12-31$4.54B$281.30M
2016-12-31$3.81B$255.30M

Dividend history

Most recent payment
Nov 13, 2026
Paid in the last twelve months
$6.92
Payment dateDividend per share
2026-11-13$1.73
2026-08-14$1.73
2026-05-15$1.73
2026-02-13$1.73
2025-11-14$1.50
2025-08-15$1.50
2025-05-16$1.50
2025-02-14$1.50

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$5.38
2026-08-05Jun 2026$6.01
2026-04-30Mar 2026$7.06
2026-02-04Dec 2025$6.99
2025-10-30Sep 2025$6.02
2025-08-07Jun 2025$5.61
2025-05-01Mar 2025$3.52
2025-02-06Dec 2024$5.03

Filings and sources

Company website
lilly.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades